ConductScience.org, home

Paper9748012

Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy. NGF Study Group.

Apfel SC and 5 others. Neurology, 1998. Cited by 250 papers, by iCite.

Cite this record

ConductScience Library. Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy. NGF Study Group. Papers, record 9748012. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/9748012

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy. NGF Study Group.
PubMed
Journal
Neurology
PubMed
Year
1998
PubMed
Publication types
Clinical Trial, Controlled Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
250
iCite
Relative citation ratio, by iCite
6.93
iCite
Revised in PubMed
2019-05-14
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Apfel SCS C
2Kessler JAJ A
3Adornato BTB T
4Litchy WJW J
5Sanders CC
6Rask CAC A

Source PubMed

Download CSV of authors

Topics13

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Diabetic NeuropathiesMajor topic
Nerve Growth FactorsMajor topic
Adolescent
Adult
Double-Blind Method
Female
Humans
Male
Middle Aged
Neural Conduction
Recombinant Proteins
Sensation
Treatment Outcome

Source PubMed

Download CSV of topics

Trials2

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's recordSource
NCT01744704Study to Evaluate Safety, Tolerability and Pharmacokinetics of rhNGF Eye Drops in Healthy VolunteersBackgroundClinicalTrials.gov
NCT03968042Efficacy and Safety of Nerve Growth Factor or Edaravone on Alcohol-induced Brain InjuryBackgroundClinicalTrials.gov

Download CSV of trials

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment in9748004Recombinant human nerve growth factor and diabetic polyneuropathy.https://conductscience.org/library/papers/9748004

Source PubMed

Download CSV of comments and corrections

Cited by70

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 250 citations.

PMIDTitleJournalYearIn PapersSource
42564001Mechanisms, translational opportunities for diabetic polyneuropathy.Front Endocrinol (Lausanne)2026https://conductscience.org/library/papers/42564001PubMed
42313885Understanding Motor Adaptation in the Transition to Sustained Pain: Protocol for a Longitudinal Experimental Study.JMIR Res Protoc2026https://conductscience.org/library/papers/42313885PubMed
41316697
Electrophysiological diagnosis using the coefficient of variation of R-R intervals and a point-of-care nerve conduction device is highly correlated to the diagnosis of diabetic polyneuropathy using conventional electromyographs.
J Diabetes Investig2026https://conductscience.org/library/papers/41316697PubMed
401535821953-2023. Seventy Years of the Nerve Growth Factor: A Potential Novel Treatment in Neurological Diseases?Aging Dis2024https://conductscience.org/library/papers/40153582PubMed
39996814NGF in Neuropathic Pain: Understanding Its Role and Therapeutic Opportunities.Curr Issues Mol Biol2025https://conductscience.org/library/papers/39996814PubMed
39315114Sustained nerve growth factor-induced C-nociceptor sensitization to electrical sinusoidal stimulation in humans.Pain Rep2024https://conductscience.org/library/papers/39315114PubMed
38429927Gene therapy approaches for obesity-induced adipose neuropathy: Device-targeted AAV-mediated neurotrophic factor delivery to adipocytes in subcutaneous adipose.Mol Ther2024https://conductscience.org/library/papers/38429927PubMed
37520975Clinical evaluation of the perception of post-trauma paresthesia in the mandible, using a biomimetic material: A preliminary study in humans.Heliyon2023https://conductscience.org/library/papers/37520975PubMed
37190099Improving Schwann Cell Differentiation from Human Adipose Stem Cells with Metabolic Glycoengineering.Cells2023https://conductscience.org/library/papers/37190099PubMed
36412335The efficacy of new neuronal growth factor in the healing of the sciatic nerves in rabbits.Ann Afr Med2022https://conductscience.org/library/papers/36412335PubMed
35127954An Insight into Potential Pharmacotherapeutic Agents for Painful Diabetic Neuropathy.J Diabetes Res2022https://conductscience.org/library/papers/35127954PubMed
34935118Neurobiological Opportunities in Diabetic Polyneuropathy.Neurotherapeutics2021https://conductscience.org/library/papers/34935118PubMed
34780798Phase 1b Randomized Controlled Study of Short Course Topical Recombinant Human Nerve Growth Factor (rhNGF) for Neuroenhancement in Glaucoma: Safety, Tolerability, and Efficacy Measure Outcomes.Am J Ophthalmol2022https://conductscience.org/library/papers/34780798PubMed
34335170Nerve Growth Factor Biodelivery: A Limiting Step in Moving Toward Extensive Clinical Application?Front Neurosci2021https://conductscience.org/library/papers/34335170PubMed
33713848The TrkA agonist gambogic amide augments skeletal adaptation to mechanical loading.Bone2021https://conductscience.org/library/papers/33713848PubMed
33641595Nerve Growth Factor as an Ocular Therapy: Applications, Challenges, and Future Directions.Semin Ophthalmol2021https://conductscience.org/library/papers/33641595PubMed
32693191A missense point mutation in nerve growth factor (NGFR100W) results in selective peripheral sensory neuropathy.Prog Neurobiol2020https://conductscience.org/library/papers/32693191PubMed
32412144Evolving concepts on the role of dyslipidemia, bioenergetics, and inflammation in the pathogenesis and treatment of diabetic peripheral neuropathy.J Peripher Nerv Syst2020https://conductscience.org/library/papers/32412144PubMed
30899338Is the Diabetic Bladder a Neurogenic Bladder? Evidence from the Literature.Curr Bladder Dysfunct Rep2014https://conductscience.org/library/papers/30899338PubMed
30675270Targeting the BDNF/TrkB pathway for the treatment of tumors.Oncol Lett2019https://conductscience.org/library/papers/30675270PubMed

See all 70 cited byDownload CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
NGF4803PubTator's text mininghttps://conductscience.org/library/genes/4803

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/9748012

GET https://conductscience.org/api/papers/v1/9748012/cited_by?page=2